ClinicalTrials.gg
CompletedNCT06132932Updated Nov 15, 2023

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

A Phase 1/2 interventional study of WX390 in PIK3CA Mutation-Related Tumors, sponsored by Shanghai Jiatan Pharmatech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Shanghai Jiatan Pharmatech Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jun 2021, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 in patients with advanced solid tumors. The main question it aims to answer is:

  • safety and preliminary efficacy in WX390 therapy. Participants will be treated with WX390 orally and follow the efficacy and safety evaluation according to the protocol.
Read the detailed description

This study is a multicenter, open-label phase Ib/IIa clinical trial for patients with advanced solid tumors who have failed standard treatment. The study adopts a basket design, divided into 6 cohorts, with a total of 70-80 advanced solid tumor patients with PIK3CA mutations enrolled. Participants will receive WX390 treatment administered continuously daily, with each cycle lasting 28 days, until disease progression or intolerable toxicity occurs. During the study, safety and efficacy will be evaluated, with efficacy assessment based on RECIST 1.1. In addition, the study will collect tumor tissue or blood samples from the participants to explore the relationship between other biomarkers and treatment efficacy, as well as the impact of changes in PIK3CA mutation status before and after treatment on efficacy.

02

Conditions studied

  • PIK3CA Mutation-Related Tumors
03

In context

Lead sponsor

Shanghai Jiatan Pharmatech Co., Ltd is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-75 years of age
  • or cytologically confirmed advanced malignant solid tumors (excluding non-small cell lung cancer) who have failed standard treatment, have no standard treatment options, or for whom standard treatment is not suitable at the current stage (colorectal cancer patients must provide genetic test results confirming KRAS wild-type)
  • (ECOG) performance status of 0-1
  • of more than 3 months
  • At least one according to 1.1
  • Adequate organic function
  • Signed and dated

Exclusion criteria

Exclusion Criteria:

  • Anti-tumor treatments such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, or immunotherapy received within 4 weeks before the first use of the study drug
  • Other unapproved clinical trial drugs or treatments received within 4 weeks before the first use of the study drug
  • Major organ surgery (excluding ) or significant trauma within 4 weeks before the first use of the study drug
  • Systemic use of or other agents within 14 days before the first use of the study drug
  • Previous treatment with PI3K, AKT, or mTOR inhibitors
  • Active infection requiring systemic anti-infection treatment
  • Known alcohol or drug dependence
  • Individuals with mental disorders or poor compliance
  • Pregnant or lactating women
  • The researcher believes that the subject has other serious systemic medical history or other reasons that make them unsuitable for participating in this clinical study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    WX390

    Participants will receive WX390 continuous oral dosing (1.1 mg once a day).

    Drug: WX390

Interventions

  • DrugWX390

    Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.

    Also known as: WXFL10030390

06

What researchers measure

Primary outcomes

  1. Safety of WX390 in treating patients with advanced malignant solid tumors harboring PIK3CA mutations.

    Safety will be evaluated by monitoring AE/SAE

    Time frame: From the start of the trial,up to 24 weeks

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of patients with complete response (CR) and partial response (PR) according to RECIST 1.1.

    Time frame: From the start of the trial,up to 24 weeks

Secondary outcomes

  1. Disease Control Rate (DCR) determined according to RECIST 1.1 criteria

    DCR is defined as the proportion of patients with complete response (CR), partial response (PR) and stable disease (SD) according to RECIST 1.1.

    Time frame: From the start of the trial,up to 24 weeks

  2. Duration of Response (DOR) determined according to RECIST 1.1 criteria

    DOR is defined as the time from the initial occurrence of a complete response (CR) or partial response (PR) until disease progression or death due to any cause.

    Time frame: From the start of the trial,up to 24 weeks

  3. Progression-Free Survival (PFS) determined according to RECIST 1.1 criteria

    PFS is defined as the time from randomization until objective tumor progression or death, whichever occurs first.

    Time frame: From the start of the trial,up to 24 weeks

07

Study locations

1 site
  • Shanghai East Hospital
    Shanghai, Shanghai 310000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jan 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 15, 2023
StartActual
Jun 3, 2021
Primary completionActual
Jan 3, 2023
CompletionActual
Jan 3, 2023
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06132932
Lead sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Responsible party
Sponsor
First posted
Nov 15, 2023
Start date
Jun 3, 2021
Primary completion
Jan 3, 2023
Completion
Jan 3, 2023
Last update
Nov 15, 2023

Study contacts

Jin Li, PhD
principal investigator · Shanghai East Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PI3K/mTOR Kinase Inhibitor WXFL10030390

Start the discussion